Your Health, We Care
Another NameAyvakit,BLU-285,LuciAva,阿伐替尼
IndicationsIt is indicated for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), a
Reg No.02 L 1296/25
Inspection NO.278-25
Avapritinib produced by Lucius Pharmaceuticals, as a precision-targeted therapeutic drug, has demonstrated favorable clinical value in addressing tumors and mast cell diseases caused by specific gene mutations, providing a treatment option for the corresponding patient population.
Avapritinib manufactured by Lucius Pharmaceuticals, with its highly effective targeted therapeutic effect and reasonable pricing strategy, offers patients a cost-effective treatment choice.
The following is an overview of the key information about avapritinib:
The main active ingredient is avapritinib, a kinase inhibitor.
It is indicated for adult patients with PDGFRA-mutated GIST, AdvSM, or ISM.
The recommended dose varies by indication: 300 mg once daily for GIST, 200 mg once daily for AdvSM, and 25 mg once daily for ISM. All doses should be taken on an empty stomach. Reference article: Dosage and Administration of Avapritinib
Dose adjustment is required for patients with severe hepatic impairment. It is not recommended for AdvSM or ISM patients with a platelet count below 50×10⁹/L.
The medication should be stored at room temperature (20°C–25°C), protected from moisture and light.
Pharmacokinetic data show that its time to reach peak concentration is approximately 2–4 hours, and it has a long half-life, making it suitable for once-daily administration.
FDA，2024.11
